The cardiovascular fitness level of cancer survivors is not affected by
many standard cancer therapies, say researchers from Georgetown
University Medical Cancer. That is the finding of a new observational
study to be presented today at the American College of Sports Medicine
in Seattle.

"We know physical activity is a critical component
of cancer survivorship, both during and after cancer treatment," says
Jennifer LeMoine, PhD, a post-doctoral research fellow with training in
exercise physiology at GUMC's Lombardi Comprehensive Cancer Center. "In
order to ... for full story - http://the-cancer-chronicles.blogspot.com/

What are your thoughts?

Thanks

Mike Bello, M.D.

Cancer Advocate

Neoplasm Research Institute


       Yahoo! Mail Now Faster and Cleaner. Experience it at
http://ph.mail.yahoo.com  today!

[Non-text portions of this message have been removed]

I will be out of the office starting  08/18/2008 and will not return until
09/02/2008.

I will respond to your message when I return.

Hope this news will help the next generation

A mathematical model to find blood biomarkers that can help doctors
estimate the size of cancer tumors has been developed by researchers at
Stanford University.



The team says its work may help guide development of new tests to
improve early detection of cancer. Currently, there's no reliable
method of using the results of blood-screening tests to gauge tumor
size.



The Stanford researchers developed... http://the-cancer-chronicles.blogspot.com/

Thanks

Mike Bello, M.D.

Cancer Advocate

Neoplasm Research Institute




[Non-text portions of this message have been removed]

Fellow Groupsmates.

I read a nice story about a man saving someone who have cancer.

Safa'a
was diagnosed in Iraq with Wilms' tumor, the most common kidney tumor
in children. If caught and treated early on, the cancer has a high
survival rate. But by the time Safa'a arrived in Jordan, Sultan says,
it was a miracle the boy was alive. "The tumor is massive," Sultan
says. "The liver, kidney, intestines are all squished to the sides. His
lungs are very small. It's hard to believe he is able to breathe."
Watch Iraq baby gets second chance here
http://the-cancer-chronicles.blogspot.com/.
The tumor prevented him from developing like other children. "Sometimes
when we see other children play, he starts to cry," his father says. "I
don't buy him certain toys like soccer balls. Because he looks at me
and when he throws it far away, he can't go and get it. Even at his
age, he understands." Continue reading
http://the-cancer-chronicles.blogspot.com/

Thanks
Mike Bello, M.D.
Cancer Advocate
Neoplasm Research Institute




[Non-text portions of this message have been removed]

I will be out of the office starting  08/11/2008 and will not return until
08/19/2008.

Please feel free to leave me an e-mail message or a message on my voice
mail. 580-249-3812 thanks  April




UHS Confidentiality Notice:  This e-mail message, including any attachments, is
for the sole use of the intended recipient (s) and may contain confidential and
privileged information.  Any unauthorized review, use, disclosure or
distribution of this information is prohibited.  If this was sent to you in
error, please notify the sender by reply e-mail and destroy all copies of the
original message.

I would like to share a website that compiles stories and updates about cancer
that would surely help us. Here is the site
http://the-cancer-chronicles.blogspot.com/
They also have a chat where doctors, patients and medical practitioners can chat
some updates about cancer and survival guides.




[Non-text portions of this message have been removed]

I am searching for a file that I thought was in this group. It was a
blank abstracting form. Any help is appreciated.
Thanks

There is a opening for a Cancer Registrar at the VA in Orlando
Florida.  This is a brand new program at what is currently a VA
Outpatient Clinic in Orlando. Plans are for a brand new "state of the
art" Medical Center scheduled to open in 2012. The job will be under
Medical Service, Oncology Section.


Department: Department Of Veterans Affairs
Agency: Veterans Affairs, Veterans Health Administration
Sub Agency: ORLANDO FL
Job Announcement Number:
ORL-08-142-PM



MEDICAL RECORDS TECHNICIAN (TUMOR REGISTRY)

Salary Range: 40,779.00 - 53,012.00 USD per year Open Period:
Wednesday, May 07, 2008
to Wednesday, May 28, 2008
Series & Grade: GS-0675-08 Position Information: Full-Time Permanent
  Duty Locations: 1 vacancy - Orlando, FL
Who May Be Considered:
Applications will be accepted from United States citizens and
nationals.
Job Summary:


The Orlando VA Medical Center, previously integrated with the James
A. Haley Veterans Hospital in Tampa, FL., was officially established
effective October 1, 2006. The Orlando VA system currently includes a
120-bed NHCU, a 60-bed Domiciliary, and a large comprehensive,
satellite outpatient clinic and CBOC systems. Active planning is
ongoing for the new "Orlando VA Medical Center," with planned
construction beginning in 2008. The Orlando VA system is located in
East-Central Florida, a family-oriented area, with many local
entertainment attractions/outdoor activities readily available.
Florida is recognized for its warm, sunny climate, beautiful beaches,
abundant housing options, and no state income tax. The Orlando VA is
associated with the University of Central Florida and other local
community colleges, with active affiliations in allied health
programs, such as Nursing, Pharmacy and Physical/Occupational Therapy.


Major Duties:
The incumbent serves as an expert tumor registrar in a large, complex
VA Medical Center with a medical/surgical oncology program with a
number of on going clinical oncology trials.  The work of the
position supports the care and treatment given to patients with
malignant conditions.  Abstracts, codes, and maintains registry
records.  Develops and monitors tumor registry quality assurance
programs and conducts related special studies.


Thoroughly searches medical records to identify and code all
information pertinent to the patient's diagnosis.  This includes
demographics, diagnosis, site and histology, diagnostic procedures,
extent of disease, and treatment.  Coding assignments may involve
highly technical, complex diagnoses/procedures.  Codes diseases,
surgical procedures, and causes of injury.  Uses specific codes
required in a cancer registry such as stage of disease, morphology,
and topography, using International Classification of Diseases for
Oncology, AJCC Staging Manual, FORDS Manual.  Independently codes a
wide variety of medical diagnostic, therapeutic, and surgical
procedures.  Analyzes the consistency of coding of registry data,
cancer diagnosis, histology, and treatment.  Submits data annually to
the VA Central Cancer Registry, per directives.  Submits data to the
American College of Surgeons' National Cancer Database annually.



Qualifications:
You must have one year of specialized experience at a level close to
the work of this job that has given you the particular knowledge,
skills, and abilities required to successfully perform. Typically we
would find this experience in work within this field or a field that
is closely related.

BASIC QUALIFICATION REQUIREMENTS

·        Citizenship of the United States

·        Licensure or Certification is not required for this
occupation; however, it is strongly desirable.

·        One year of experience, which is in or related to the line
of work of the position to be filled and which has equipped the
applicant with the specific knowledge, skills, and abilities to
successfully perform the duties of the position.


You must be a U.S. citizen to qualify for this position.

After appointment, you will be subject to random testing for illegal
drug use.

You will need to successfully complete a background security
investigation before you can be appointed into this position.

You must meet time-in-grade restrictions by the closing date of this
announcement.

Applicants for this position must pass a pre-employment medical
examination.

How You Will Be Evaluated:
You will be evaluated to determine if you meet the minimum
qualifications required; and on the extent to which your application
shows that you possess the knowledges, skills, and abilities
associated with this position as defined below. You MUST address the
KSAs on a separate sheet of paper.  Failure to respond to the KSAs
will result in an incomplete application.  When describing your
knowledges, skills, and abilities, please be sure to give examples
and explain how often you used these skills, the complexity of the
knowledge you possessed, the level of the people you interacted with,
the sensitivity of the issues you handled, etc.

KSAs:

1.  Ability to apply knowledge of medical terminology, human
anatomy/pathophysiology, and disease processes sufficient to
appropriately file, locate, and disclose health information.

2.  Advanced knowledge of medical terminology, staging of cancer, and
requirements of external approving organizations.

3.  Knowledge of the design, conduct, and interpretation of case
ascertained, re-abstracting, and quality assurance studies.

4.  Knowledge of cancer committee processes and procedures in order
to improve patient care and to verify compliance.

5.  Ability to correctly apply a practical knowledge of laws and
regulations related to the confidentiality of health information and
the release of information from medical records.

6.  Ability to manage priorities and coordinate work in order to
complete duties in an accurate and timely fashion.



Benefits:
You may participate in the Federal Employees Health Benefits program,
with costs shared with your employer. More info:
http://www.usajobs.gov/jobextrainfo.asp#FEHB.

Life insurance coverage is provided. More info:
http://www.usajobs.gov/jobextrainfo.asp#life

Long-Term Care Insurance is offered and carries into your retirement.
More info: http://www.usajobs.gov/jobextrainfo.asp#ltci

New employees are automatically covered by the Federal Employees
Retirement System (FERS). If you are transferring from another agency
and covered by CSRS, you may continue in this program. More info:
http://www.usajobs.gov/jobextrainfo.asp#retr

You will earn annual vacation leave. More info:
http://www.usajobs.gov/jobextrainfo.asp#VACA

You will earn sick leave. More info:
http://www.usajobs.gov/jobextrainfo.asp#SKLV

You will be paid for federal holidays that fall within your regularly
scheduled tour of duty. More info:
http://www.usajobs.gov/jobextrainfo.asp#HOLI

Qualified federal employees may be covered by our child care subsidy
program or dependent care flexible spending account. Our human
resources office can provide additional information on eligibility.
More info: http://www.usajobs.gov/jobextrainfo.asp#CCRS

Under a special program, we may reimburse a part of your Federally
insured student loan. Our human resources office can provide
additional information on the program.

You can use Health Care Flexible Spending Accounts for expenses that
are tax-deductible, but not reimbursed by any other source, including
out-of-pocket expenses and non-covered benefits under their FEHB
plans. More Info: http://www.usajobs.gov/jobextrainfo.asp#FSA

Other Information:
This job is being filled by an alternative hiring process and is not
in the competitive civil service.

The materials you send with your application will not be returned.

If you fax your application, we will not consider it.

Send only those materials needed to evaluate your application. Please
do not place your application in a notebook or binder.

You will be required to serve a probationary period of 2 years.



How To Apply:
You must submit your application so that it will be received by the
closing date of the announcement.


1. OF 612, or resume.

2. OF 306, Declaration for Federal employment.

3. A Narrative assessment of your qualifications as they relate to
the Knowledge, Abilities, Skills (KSA's) identified within this
announcement.  If a Supplemental Qualification Statement is not
included in this announcement, the KSA's may be addressed on bond
paper and attached to your application package.

4. If you are claiming veterans' preference, you must provide a copy
of your military discharge, DD 214 (member 4 copy), or Certificate of
Release or Discharge from Active Duty.

5. If you are a current or former federal employee with reinstatement
eligibility, you must submit a copy of your last Notification of
Personnel Action (SF50) and a copy of your most recent Performance
Appraisal.

The Orlando VA does not accept E-mail, on-line or faxed applications.

Application mailed using government postage or through an internal
federal government mail system will not be considered.



Contact Information:
Michael V. Brown
Phone: 321-397-6540
Email: Michael.Brown2@...

Or write:
ORLANDO VA MEDICAL CENTER
5201 Raymond Street
Orlando, FL 32803
US


What To Expect Next:
Once your complete application is received we will conduct an
evaluation of your qualifications and determine your ranking. The
most highly qualified candidates will be referred to the hiring
manager for further consideration and possible interview. We expect
to make a selection within 30 days of the closing date of this
announcement. You will be notified of the outcome.








The United States Government does not discriminate in employment on
the basis of race, color, religion, sex, national origin, political
affiliation, sexual orientation, marital status, disability, age,
membership in an employee organization, or other non-merit factor.









Federal agencies must provide reasonable accommodation to applicants
with disabilities where appropriate. Applicants requiring reasonable
accommodation for any part of the application and hiring process
should contact the hiring agency directly. Determinations on requests
for reasonable accommodation will be made on a case-by-case basis.










  Send Mail to:
ORLANDO VA MEDICAL CENTER
5201 Raymond Street
Orlando, FL 32803
US


  For questions about this job:
Michael V. Brown
Phone: 321-397-6540
Email: Michael.Brown2@...




USAJOBS Control Number: 1214286

Had a great time meeting registrars across the country!  The
presentations were informative and interesting( for the most part).

I will be out of the office starting  04/25/2008 and will not return until
05/05/2008.

Please feel free to leave me an e-mail message or a message on my voice
mail. 580-249-3812 thanks  April




UHS Confidentiality Notice:  This e-mail message, including any attachments, is
for the sole use of the intended recipient (s) and may contain confidential and
privileged information.  Any unauthorized review, use, disclosure or
distribution of this information is prohibited.  If this was sent to you in
error, please notify the sender by reply e-mail and destroy all copies of the
original message.

I will be out of the office starting  04/26/2008 and will not return until
05/05/2008.

If you need immediate assistance, please call my manager, Toni Bausch at
513-624-3223.




CONFIDENTIALITY NOTICE:  This message, including any attachments, is for
the sole use of the intended recipient(s) and may contain confidential and
privileged information.  Any unauthorized review, use, disclosure or
distribution
is prohibited.  If you are not the intended recipient, please contact the
sender by reply e-mail and destroy all copies of the original message.

I heard it too. But I am not sure if anyone out there is practicing it. It is
also mentioned in "Marketing Cancer Information and Services" publication (page
85). Again this publication was publsihed in 1995.



Cherian Mathew

  __________________________________________________
Do You Yahoo!?
Tired of spam?  Yahoo! Mail has the best spam protection around
http://mail.yahoo.com

[Non-text portions of this message have been removed]

Due to hospital cutbacks, my department was asked if there was ways we could
find to be revenue producing to offset cost. Many years ago there was talk of
being able to charge insurance companies a one time fee for being placed in the
cancer registry. Did anything ever become of this

__________________________________________________
Do You Yahoo!?
Tired of spam?  Yahoo! Mail has the best spam protection around
http://mail.yahoo.com

[Non-text portions of this message have been removed]

We are an office of 2 CTRs.
We accession ~1000 cases annually.
We follow ~6200 pts a year. (Our registry is 21 years old with the
original reference year.)
We do all our own quality checks and hold the doctors' hand when they
do their review.
We have weekly general tumor board and bi-weekly lung board. The Heme
dept holds a bi-weekly lymphoma board and we just keep stats for
them.

We have 2 volunteers for a total of 5 hours a week. They collate,
file, do data entry, etc.
We presented to Administration the need to create a succession plan.
Since it takes 3-5 years to home-grow a registrar, it isn't too early
to plan.
I would prefer to forgo the volunteers and hire in at least a part-
time registrar; if not a FT one.

Nancyctr

--- In cancerregistrargroup@yahoogroups.com, loril_ga <no_reply@...>
wrote:
>
> I am a single registrar at a hospital and since I started the
caseload
> has gone from 500+ cases to over 900+ for 2007.  I am trying to
justify
> the hiring of at least one more FTE.  We are not an approved
program
> but hope to be sometime in 2009.  We have monthly tumor conferences
and
> cancer committee every other month (6 a year).  I do everything
that is
> required for an ACOS program....abstract, follow up, casefinding,
QA,
> tumor conference, cancer committee, studies, etc.
>
> I would like to hear from others with the same caseload and how
many
> FTE's they have in order to have information to back my request for
> additional help.  Please either post here or email me at
> Loraine.Lindsey@...
>

Melanoma metastatic to the brain (MRI) and axillary and inguinal lymph
nodes (LN biopsy).  Primary skin site cannot be determined.  How would
you TNM this using AJCC:


Primary Site:  C449
Histology:     M8720/3


CT0 CNX CM1C, Stage IV
PTX PNX PM1C, Stage IV

LNS exam/+ 99/99
Scope 9
  How would you collaborative stage this?
CS tumor size 000          CS ext          95       CS ext eval  0
CS LNs         99          CS lns eval      9
CS Mets        54 (10+44)  CS mets eval     1

I will be out of the office starting  02/08/2008 and will not return until
02/14/2008.




CONFIDENTIALITY NOTICE:  This message, including any attachments, is for
the sole use of the intended recipient(s) and may contain confidential and
privileged information.  Any unauthorized review, use, disclosure or
distribution
is prohibited.  If you are not the intended recipient, please contact the
sender by reply e-mail and destroy all copies of the original message.

That sounds like a Donna Gress question.  I would ask her that
specifically.

veronica shrode



--- In cancerregistrargroup@yahoogroups.com, "nkawesch" <kaweschn@...>
wrote:
>
> Parotid Gland Primary - C079.  Histology:  Carcinoma in situ arising
in
> a pleomorphic adenoma - M8941/2.  AJCC, page 70, does not have a Tis
> value.  However, CS allows for cs extension to be 00 and derives to
> PTis, Stage 0.  Will there be a change in AJCC or this an oversight
in
> CS? Referenced AJCC and CS.  How would you code this using AJCC?
>

Parotid Gland Primary - C079.  Histology:  Carcinoma in situ arising in
a pleomorphic adenoma - M8941/2.  AJCC, page 70, does not have a Tis
value.  However, CS allows for cs extension to be 00 and derives to
PTis, Stage 0.  Will there be a change in AJCC or this an oversight in
CS? Referenced AJCC and CS.  How would you code this using AJCC?

I am a single registrar at a hospital and since I started the caseload
has gone from 500+ cases to over 900+ for 2007.  I am trying to justify
the hiring of at least one more FTE.  We are not an approved program
but hope to be sometime in 2009.  We have monthly tumor conferences and
cancer committee every other month (6 a year).  I do everything that is
required for an ACOS program....abstract, follow up, casefinding, QA,
tumor conference, cancer committee, studies, etc.

I would like to hear from others with the same caseload and how many
FTE's they have in order to have information to back my request for
additional help.  Please either post here or email me at
Loraine.Lindsey@....

Thanks, but I do not see anything specific to pleural effusion
laterality on the cs page mentioned or repeated in the 2004 seer
manual. Answers to questions in formats such as I&R and Seer inquiry
are good resources if they can back up their answers with specific
information from our manuals. If registrars are not privy to FAQ
formats, they may not get the needed interpretation to stage
correctly.  I am seeing this phenomenon more with the new MPH rules
also.

--- In cancerregistrargroup@yahoogroups.com, "meeeum"
<miriwilliams@...> wrote:
>
>
> From SEER Inquiry System, <http://seer.cancer.gov/seerinquiry/>   ID
> 20041090
>
> References
> 1. CS Manual, Part II ;pgs 409 (Vers 1.0, Jan. 1, 2004)
> 2. 2004 SEER Manual ;pgs C-391 (Appendix C)   Brief
> Question
> CS Extension/CS Mets at DX--Lung: How do you code bilateral pleural
> effusion for a right lung primary in the Collaborative Staging
system?
> Please see discussion below.
> Answer
> For bilateral malignant pleural effusion, code the ipsilateral
malignant
> effusion in CS Extension and the contralateral malignant effusion in
> Mets at DX. Assuming the bilateral pleural effusion is the furthest
> extension in this case, code CS Extension to 72 [Malignant pleural
> effusion]. Code CS Mets at DX to 40 [Distant mets, NOS].
>
>
>
> --- In cancerregistrargroup@yahoogroups.com, muzactr <no_reply@>
> wrote:
> >
> > Could someone please direct me to where in any of our Standard
> Setter's
> > Manuals there is a rule/guideline or just a discussion on how to
stage
> > pleural effusions depending on whether they are ipsilateral,
> > contralateral or bilateral to the lung cancer prim site in
question.
> >
> > Most references in the manuals refer to pleural effusion, nos or
> > pleural effusion, malign and do not distinguish laterality, but it
> > seems that for staging ipsi is t4 and bi or contra is M1, but if
it is
> > not documented to do it that way somewhere, then how will
everybody do
> > it the same way. I have been doing abstracting for over 16 years
and
> > cannot remember reading about this anywhere.
> >
> >
> > I have already submitted this question to I&R and was told to
look at
> > the AJCC Staging Manual,6th edition, page 175, but do not see
anything
> > there about this.
> >
>
>
>
>
> [Non-text portions of this message have been removed]
>

From SEER Inquiry System, <http://seer.cancer.gov/seerinquiry/>   ID
20041090

References
1. CS Manual, Part II ;pgs 409 (Vers 1.0, Jan. 1, 2004)
2. 2004 SEER Manual ;pgs C-391 (Appendix C)   Brief
Question
CS Extension/CS Mets at DX--Lung: How do you code bilateral pleural
effusion for a right lung primary in the Collaborative Staging system?
Please see discussion below.
Answer
For bilateral malignant pleural effusion, code the ipsilateral malignant
effusion in CS Extension and the contralateral malignant effusion in
Mets at DX. Assuming the bilateral pleural effusion is the furthest
extension in this case, code CS Extension to 72 [Malignant pleural
effusion]. Code CS Mets at DX to 40 [Distant mets, NOS].



--- In cancerregistrargroup@yahoogroups.com, muzactr <no_reply@...>
wrote:
>
> Could someone please direct me to where in any of our Standard
Setter's
> Manuals there is a rule/guideline or just a discussion on how to stage
> pleural effusions depending on whether they are ipsilateral,
> contralateral or bilateral to the lung cancer prim site in question.
>
> Most references in the manuals refer to pleural effusion, nos or
> pleural effusion, malign and do not distinguish laterality, but it
> seems that for staging ipsi is t4 and bi or contra is M1, but if it is
> not documented to do it that way somewhere, then how will everybody do
> it the same way. I have been doing abstracting for over 16 years and
> cannot remember reading about this anywhere.
>
>
> I have already submitted this question to I&R and was told to look at
> the AJCC Staging Manual,6th edition, page 175, but do not see anything
> there about this.
>




[Non-text portions of this message have been removed]

Could someone please direct me to where in any of our Standard Setter's
Manuals there is a rule/guideline or just a discussion on how to stage
pleural effusions depending on whether they are ipsilateral,
contralateral or bilateral to the lung cancer prim site in question.

Most references in the manuals refer to pleural effusion, nos or
pleural effusion, malign and do not distinguish laterality, but it
seems that for staging ipsi is t4 and bi or contra is M1, but if it is
not documented to do it that way somewhere, then how will everybody do
it the same way.  I have been doing abstracting for over 16 years and
cannot remember reading about this anywhere.


I have already submitted this question to I&R and was told to look at
the AJCC Staging Manual,6th edition, page 175, but do not see anything
there about this.

remember to use pathology from most definitive specimen - which would
be from sx in this case and  8522/3...



--- In cancerregistrargroup@yahoogroups.com, kaweschn@... wrote:
>
> Sorry for the typo I have corrected it below
>
> Nancy Kawesch, MS, CTR
> Manager, Cancer Database
>
> Memorial Sloan-Kettering Cancer Center
> 633 Third Avenue, 18th Floor
> New York, New York 10017
> Phone:              646-227-2031; Mondays: 914-738-0561
> Fax:                   212-557-0314
> E-mail:              Kaweschn@...
>
>
>
>
> > _____________________________________________
> > From:  Kawesch, Nancy/Clinical Systems Admin
> > Sent: Wednesday, January 30, 2008 2:26 PM
> > To: 'cancerregistrargroup@yahoogroups.com'
> > Cc: Assante, Tara/Clinical Systems Admin; Gallo, Latasha/Clinical
Systems Admin; Horvath, Eva/Clinical Systems Admin; Johnson,
Susan/Clinical Systems Admin; Kawesch, Nancy/Clinical Systems Admin;
Laterza, Carol/Clinical Systems Admin; Lawrence, Jean/Clinical
Systems Admin; McCormick, Eartha/Clinical Systems Admin; Morrobel,
Janet/Clinical Systems Admin; Moser, Christine/Clinical Systems
Admin; Ramos, Lisa/Clinical Systems Admin; Sang, Nicole C./Clinical
Systems Admin; Yates, Denise/Clinical Systems Admin; Yi,
Anna/Clinical Systems Admin; Zelenak, Elvira/Clinical Systems Admin
> > Subject:  Re:Question 2
> >
> > After much discussion, This is how our thought processes went:
> >
> > If, you presume there are 3 histological types, 1 primary:
> > * Mucinous
> > * Infiltrating duct
> > * Infiltrating lobular
> >
> >
> > Then Histology:  M8523/3 - Use H17
> >
> > If you presume there are 2 histological types, 1 primary:
> > * Infiltrating duct
> > * Infiltrating lobular
> >
> > Then Histology:  M8522/3 - Use H16
> >
> >
> >
> > It would be helpful to have others' thought processes.  Thank you.
> >
> >
> > Nancy Kawesch, MS, CTR
> > Manager, Cancer Database
> >
> > Memorial Sloan-Kettering Cancer Center
> > 633 Third Avenue, 18th Floor
> > New York, New York 10017
> > Phone:              646-227-2031; Mondays: 914-738-0561
> > Fax:                   212-557-0314
> > E-mail:              Kaweschn@...
> >
> >
> >
>
>
> [Non-text portions of this message have been removed]
>

Sorry for the typo I have corrected it below

Nancy Kawesch, MS, CTR
Manager, Cancer Database

Memorial Sloan-Kettering Cancer Center
633 Third Avenue, 18th Floor
New York, New York 10017
Phone:              646-227-2031; Mondays: 914-738-0561
Fax:                   212-557-0314
E-mail:              Kaweschn@...




> _____________________________________________
> From:  Kawesch, Nancy/Clinical Systems Admin
> Sent: Wednesday, January 30, 2008 2:26 PM
> To: 'cancerregistrargroup@yahoogroups.com'
> Cc: Assante, Tara/Clinical Systems Admin; Gallo, Latasha/Clinical Systems
Admin; Horvath, Eva/Clinical Systems Admin; Johnson, Susan/Clinical Systems
Admin; Kawesch, Nancy/Clinical Systems Admin; Laterza, Carol/Clinical Systems
Admin; Lawrence, Jean/Clinical Systems Admin; McCormick, Eartha/Clinical Systems
Admin; Morrobel, Janet/Clinical Systems Admin; Moser, Christine/Clinical Systems
Admin; Ramos, Lisa/Clinical Systems Admin; Sang, Nicole C./Clinical Systems
Admin; Yates, Denise/Clinical Systems Admin; Yi, Anna/Clinical Systems Admin;
Zelenak, Elvira/Clinical Systems Admin
> Subject:  Re:Question 2
>
> After much discussion, This is how our thought processes went:
>
> If, you presume there are 3 histological types, 1 primary:
> * Mucinous
> * Infiltrating duct
> * Infiltrating lobular
>
>
> Then Histology:  M8523/3 - Use H17
>
> If you presume there are 2 histological types, 1 primary:
> * Infiltrating duct
> * Infiltrating lobular
>
> Then Histology:  M8522/3 - Use H16
>
>
>
> It would be helpful to have others' thought processes.  Thank you.
>
>
> Nancy Kawesch, MS, CTR
> Manager, Cancer Database
>
> Memorial Sloan-Kettering Cancer Center
> 633 Third Avenue, 18th Floor
> New York, New York 10017
> Phone:              646-227-2031; Mondays: 914-738-0561
> Fax:                   212-557-0314
> E-mail:              Kaweschn@...
>
>
>


[Non-text portions of this message have been removed]

After much discussion, This is how our thought processes went:

If, you presume there are 3 histological types, 1 primary:
* Mucinous
* Infiltrating duct
* Infiltrating lobular


Then Histology:  M8523/3 - Use H17

If you presume there are 2 histological types, 1 primary:
* Infiltrating duct
* Infiltrating lobular

Then Histology:  M8523/3 - Use H16



It would be helpful to have others' thought processes.  Thank you.


Nancy Kawesch, MS, CTR
Manager, Cancer Database

Memorial Sloan-Kettering Cancer Center
633 Third Avenue, 18th Floor
New York, New York 10017
Phone:              646-227-2031; Mondays: 914-738-0561
Fax:                   212-557-0314
E-mail:              Kaweschn@...





      =====================================================================

      Please note that this e-mail and any files transmitted with it may be
      privileged, confidential, and protected from disclosure under
      applicable law. If the reader of this message is not the intended
      recipient, or an employee or agent responsible for delivering this
      message to the intended recipient, you are hereby notified that any
      reading, dissemination, distribution, copying, or other use of this
      communication or any of its attachments is strictly prohibited.  If
      you have received this communication in error, please notify the
      sender immediately by replying to this message and deleting this
      message, any attachments, and all copies and backups from your
      computer.


[Non-text portions of this message have been removed]

I would think it is one primary histo M8523/3
Curious what others think?

Nancy Kawesch, MS, CTR
Manager, Cancer Database

Memorial Sloan-Kettering Cancer Center
633 Third Avenue, 18th Floor
New York, New York 10017
Phone:              646-227-2031; Mondays: 914-738-0561
Fax:                   212-557-0314
E-mail:              Kaweschn@...





      =====================================================================

      Please note that this e-mail and any files transmitted with it may be
      privileged, confidential, and protected from disclosure under
      applicable law. If the reader of this message is not the intended
      recipient, or an employee or agent responsible for delivering this
      message to the intended recipient, you are hereby notified that any
      reading, dissemination, distribution, copying, or other use of this
      communication or any of its attachments is strictly prohibited.  If
      you have received this communication in error, please notify the
      sender immediately by replying to this message and deleting this
      message, any attachments, and all copies and backups from your
      computer.


[Non-text portions of this message have been removed]

Another breast case.....

Biopsy showed 8:00 breast with mucinous type infil ductal ca. 9:00
breast with infil ductal and infil lobular ca with DCIS.

Surgery showed infiltrating mixed ductal and lobular carcinoma, grade
2, 3.5 cm with extensive DCIS and LCIS.  0/24 nodes and negative
margins.

What is the histology?  Is this two primaries?

Somehow I think this group will be more effective if the question is posted
along with the answer - otherwise it is hard to keep track.  Not sure who the
keeper of this group is.  Thanks.

Nancy Kawesch, MS, CTR
Manager, Cancer Database

Memorial Sloan-Kettering Cancer Center
633 Third Avenue, 18th Floor
New York, New York 10017
Phone:              646-227-2031; Mondays: 914-738-0561
Fax:                   212-557-0314
E-mail:              Kaweschn@...





      =====================================================================

      Please note that this e-mail and any files transmitted with it may be
      privileged, confidential, and protected from disclosure under
      applicable law. If the reader of this message is not the intended
      recipient, or an employee or agent responsible for delivering this
      message to the intended recipient, you are hereby notified that any
      reading, dissemination, distribution, copying, or other use of this
      communication or any of its attachments is strictly prohibited.  If
      you have received this communication in error, please notify the
      sender immediately by replying to this message and deleting this
      message, any attachments, and all copies and backups from your
      computer.


[Non-text portions of this message have been removed]

--- In cancerregistrargroup@yahoogroups.com, ebennett40 <no_reply@...>
wrote:
>
> Rule H6 in the Multiple Primary & Histology manual would apply to
this
> case:  Code 8523/2 (intraductal carcinoma mixed with other types of
in
> situ carcinoma) when there is a combination of intraductal carcinoma
> and one or more specific intraductal types
>


I agree with Ebennet.  8523/2 per MP/H Rule H6.

The Georgia Tumor Registrar's Association is holding their bi-annual
CTR Workshop in McDonough Georgia February 22 & 23rd.  For more
information email me or go to www.gatraweb.org.  My email is
lorilindsey@....